OKLAHOMA CITY – A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients whose disease returns after radiation therapy – a setback that affects up to 40% of patients and is often associated with poor outcomes.
For these patients, surgery is currently the standard treatment, typically targeting tumors in the mouth, throat or lymph nodes of the neck. This Phase II trial will examine whether giving chemotherapy, or chemotherapy combined with immunotherapy, before surgery can improve survival compared with surgery alone.
Thursday, February 26, 2026 @ 3:00 PM - Thursday, February 26, 2026 @ 4:00 PM
Zoom
Wednesday, March 4, 2026 @ 1:00 PM - Wednesday, March 4, 2026 @ 2:00 PM
Tuesday, March 10, 2026 @ 4:00 PM - Tuesday, March 10, 2026 @ 5:00 PM
Tuesday, March 31, 2026 @ 5:00 PM - Tuesday, March 31, 2026 @ 7:00 PM
Microsoft Teams
Wednesday, April 1, 2026 @ 1:00 PM - Wednesday, April 1, 2026 @ 2:00 PM
Thursday, April 2, 2026 @ 12:00 PM - Thursday, April 2, 2026 @ 2:00 PM
Oklahoma State University, Student Union - North Plaza
Thursday, April 2, 2026 @ 3:00 PM - Thursday, April 2, 2026 @ 4:00 PM
Tuesday, April 7, 2026 @ 11:30 AM
Oklahoma Christian University, Garvey Center